Organoid-guided vs topotecan for relapsed extensive-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial compares a treatment plan guided by lab-grown tumor samples (organoids) to standard chemotherapy (topotecan) for people whose extensive-stage small cell lung cancer has come back after initial treatment. It aims to find out which approach works better for your specific cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have extensive-stage small cell lung cancer (cancer that has spread beyond one side of the chest) that has returned or worsened within 6 months of finishing your first platinum-based chemotherapy.
- You have a tumor sample or fluid from around the lung that can be used to grow organoids (miniature versions of your cancer) to test treatments.
- You have at least one measurable tumor on scans, and you are able to perform daily activities without significant help (ECOG score 0 or 1).
- You agree to use effective contraception during treatment and for 6 months after, if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a second course of chemotherapy and an immunotherapy drug (atezolizumab) for people with extensive-stage small cell lung cancer that has returned after initial treatment. The goal is to see if re-using these treatments together can help control the cancer again.
This trial tests a combination of two drugs, sacituzumab tirumotecan and anlotinib, for people with extensive-stage small cell lung cancer that has worsened after at least two cycles of standard chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a new drug called sacituzumab govitecan against the usual treatments for people with extensive-stage small cell lung cancer that has gotten worse after initial chemotherapy. It aims to see if the new drug helps patients live longer or have better outcomes.
This study uses a patient's own tumor cells grown in the lab (called an organoid) to find the most effective drug for recurrent small cell lung cancer. It aims to personalize treatment after standard therapy stops working.
This trial tests a new drug called HS-20093 against a standard drug (topotecan) for people with small cell lung cancer that has returned after initial treatment. The goal is to see which drug works better.
This study tests a new drug (GSK5764227) for people whose extensive-stage small cell lung cancer has gotten worse after platinum chemotherapy combined with immunotherapy. The goal is to see if this targeted treatment can help shrink tumors and control the cancer.
Hear when a new Extensive-stage Small Cell Lung Cancer (ES-SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.